

Special Issue

Translational Approach to Antitumor Drugs - 2nd Edition

Message from the Guest Editors

In recent decades, a significant step was achieved when malignancies started to be managed as chronic diseases. However, cancer remains a big problem and there is a huge need for new effective drugs and treatments. As a continuation to the previous Special Issue, we will cover a wide range of drug development topics, including research of molecular biomarkers, pattern identification, and pro-drugs design.

Development of new drugs and treatments involves a broad translational approach to research that includes various topics, i.e., treatment methods and types, new small molecules, newly synthesized organic compounds, synthetic or purified natural products originating from the sea or on land, medical devices and inorganic compounds, and novel biomarkers. In this issue, we will put the focus on the translational potential of data generated within the drug development process. This issue therefore aims to provide an extended forum for dissemination of the latest information on some new potential anticancer drugs, treatments or drug targets, and methods for testing of their potential. Clinical trial data is accordingly appropriate for submission as well.

Guest Editors

Prof. Dr. Krešimir Pavelić

Faculty of Medicine, Juraj Dobrila University of Pula, Pula, Croatia

Prof. Dr. Sandra Kraljević Pavelić

Faculty of Health Studies, University of Rijeka, Rijeka, Croatia

Deadline for manuscript submissions

closed (28 February 2022)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/77762

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).